Metronidazole Loaded Polycaprolactone-Carbopol blends Based Biodegradable Intrapocket Dental Film for Local Treatment of Periodontitis

2020 ◽  
Vol 10 ◽  
Author(s):  
Nitin Dhedage ◽  
Gayasuddin Khan ◽  
Gufran Ajmal ◽  
Manish Kumar ◽  
Abhishek Jha ◽  
...  
Keyword(s):  
Drug Release ◽  
Gingival Crevicular Fluid ◽  
Local Treatment ◽  
Local Drug Delivery ◽  
Release Kinetic ◽  
Burst Release ◽  
Drug Release Profile ◽  
Initial Zone

: The goal of this research was to produce intrapocket dental film, composed of polycaprolactone and carbopol blends by a modified solvent casting method. Prepared films were consistent in thickness (2.10±0.56 to 2.50±0.39 mm) and weight (35.23±0.37 to 39.45±0.45 mg) with drug entrapment of up to 87.63±1.98 percent. The concentration of carbopol is observed to have a direct relationship with thickness, film weight, and swelling factor of the prepared dental film. The film has a surface pH close to gingival crevicular fluid pH and is therefore appropriate for the application. The developed film exhibited a biphasic drug release profile with an initial burst release followed by a continuous release for more than 11 days. Drug release kinetic study supports the release of the drug by a diffusion-based process, as best explained by the Korsmeyer Peppas kinetics (R2 = 0.9635). In-vitro antimicrobial activity was also in accordance with drug release, with a high initial zone of inhibition (ZOI) (49.32±0.156mm), followed by 14.28±0.080 mm ZOI on 11th day. The in-vivo study showed that the prepared film was able to prevent periodontal ligament degeneration as observed in the periodontitis experiment animal model. In conclusion, prepared intrapocket dental film based on caprolactone and carbopol can be used as a novel local drug delivery system for the management of periodontitis.

scholarly journals FORMULATION AND IN VITRO–IN VIVO PHARMACOKINETIC EVALUATION OF CARDIOVASCULAR DRUG-LOADED PULSATILE DRUG DELIVERY SYSTEMS

2021 ◽  
pp. 144-151
Author(s):  
KUMAR BABU PASUPULETI ◽  
VENKATACHALAM A. ◽  
BHASKAR REDDY KESAVAN
Keyword(s):  
Drug Release ◽  
Ethyl Cellulose ◽  
Release Kinetic ◽  
In Vitro Drug Release ◽  
The Core ◽  
Coated Tablet ◽  
Tablet Formulations ◽  
Core Tablet

Objective: This study is to formulate Nebivolol into a Pulsatile liquid, solid composite compression coated tablet, which will delay the release of the drug in early morning hypertension conditions. Methods: The liquid, solid composite tablet was formulated and compressed with the ethylcellulose coating polymer. The percent in vitro drug release of the liquid solid composite compressed tablet was tested. Based on disintegration time and wetting time, the LCS2, LCS3, LSC6, LCS7 and LCS12 formulations were found to be the optimized solid-liquid compacts fast-dissolving core tablet formulations, which may be excellent candidates for further coating with polymer to transfer into press coated pulsatile tablet formulations. Coating the core tablet with varying ethyl cellulose concentrations resulted in five different formulations of the pulsatile press-coated tablet (CT1, CT2, CT3, CT4, CT5). In vitro drug release, in vitro release, kinetic studies, in vivo pharmacokinetic and stability tests were all performed for the prepared pulsatile press coated tablet. Results: CT3 tablets are coated with ethyl cellulose polymer, which shows maximum controlled drug release from the core tablet i.e. 96.34±1.2% at 8th h. It shows there was an efficient delay in drug release form core tablet i.e. up to 3 h, followed by the maximum amount of drug release of 96.34±2.4 at 8h. Which shows the core drug will be more efficiently protected from the gastric acid environment 1.2 pH, duodenal environment 4.0 pH and release drug only in the small intestine. Conclusion: According to the findings, CT3 Pulsatile press-coated tablet increased the bioavailability of Nebivolol by 3.11 percent.

Drug release profile and reduction in the in vitro burst release from pectin/HEMA hydrogel nanocomposites crosslinked with titania

RSC Advances ◽  
2016 ◽  
Vol 6 (23) ◽  
pp. 19060-19068 ◽  
Author(s):  
Elisangela P. da Silva ◽  
Marcos R. Guilherme ◽  
Francielle P. Garcia ◽  
Celso V. Nakamura ◽  
Lucio Cardozo-Filho ◽  
...  
Keyword(s):  
Controlled Release ◽  
Drug Release ◽  
Release Profile ◽  
Burst Release ◽  
Drug Release Profile ◽  
Initial Release ◽  
Hydrogel Nanocomposites

Hydrogel nanocomposites of pectin, HEMA and titania for Vit-B12 controlled release with reduced initial release burst were prepared. A reduction of up to ca. 60% was observed.

Long-lasting in situ forming Implant loaded with Bupivacaine: Investigation on the Polymeric and Non-polymeric Carrier and Solvent Effect

2021 ◽  
Vol 18 ◽  
Author(s):  
Saeed Bazraee ◽  
Hamid Mobedi ◽  
Arezuo Mashak ◽  
Ahmad Jamshidi
Keyword(s):  
Drug Release ◽  
In Vitro Release ◽  
Fickian Diffusion ◽  
Morphological Properties ◽  
Burst Release ◽  
Solvent Concentration ◽  
Drug Release Profile ◽  
In Situ Forming

Introduction: Typically, in situ forming implants utilize Poly (lactide-co-glycolide) (PLGA) as a carrier and N-methyl-2-pyrrolidone (NMP) as a solvent. However, it is essential to develop different carriers to release various drugs in a controlled and sustained manner with economic and safety considerations. Objective: The present study aims to evaluate the in-vitro release of Bupivacaine HCl from in situ forming systems as post-operative local anesthesia. Methods: We used Sucrose acetate isobutyrate (SAIB), PLGA 50:50, and a mixture of them as carriers to compare the release behavior. Besides, the effect of PLGA molecular weight (RG 502H, RG 503H, and RG 504H), solvent type, and solvent concentration on the drug release profile was evaluated. The formulations were characterized by investigating their in-vitro drug release, rheological properties, solubility, and DSC, in addition to their morphological properties. Furthermore, the Korsmeyer-Peppas and Weibull models were applied to the experimental data. The results revealed that a mixture of SAIB and PLGA compared to using them solely can extend the Bupivacaine HCl release from 3 days to two weeks. Results: The DSC results demonstrated the compatibility of the mixture by showing a single Tg. The formulation with NMP had a higher burst release and final release in comparison with other solvents by 30% and 96%, respectively. Increasing the solvent concentration from 12% to 32% raised the drug release significantly, which confirmed the larger porosity in the morphology results. From the Korsmeyer-Peppas model, the mechanism of drug release is predicted to be non-Fickian diffusion.

scholarly journals Preparation and Evaluation of Intraperitoneal Long-Acting Oxaliplatin-Loaded Multi-Vesicular Liposomal Depot for Colorectal Cancer Treatment

Pharmaceutics ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 736
Author(s):  
Sharif Md Abuzar ◽  
Eun Jung Park ◽  
Yeji Seo ◽  
Juseung Lee ◽  
Seung Hyuk Baik ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Drug Release ◽  
Entrapment Efficiency ◽  
Lag Phase ◽  
Burst Release ◽  
Sustained Drug Release ◽  
Long Acting ◽  
High Entrapment Efficiency

Colorectal cancer with peritoneal metastasis has a poor prognosis because of inadequate responses to systemic chemotherapy. Cytoreductive surgery followed by intraperitoneal (IP) chemotherapy using oxaliplatin has attracted attention; however, the short half-life of oxaliplatin and its rapid clearance from the peritoneal cavity limit its clinical application. Here, a multivesicular liposomal (MVL) depot of oxaliplatin was prepared for IP administration, with an expected prolonged effect. After optimization, a combination of phospholipids, cholesterol, and triolein was used based on its ability to produce MVL depots of monomodal size distribution (1–20 µm; span 1.99) with high entrapment efficiency (EE) (92.16% ± 2.17%). An initial burst release followed by a long lag phase of drug release was observed for the MVL depots system in vitro. An in vivo pharmacokinetic study mimicking the early postoperative IP chemotherapy regimen in rats showed significantly improved bioavailability, and the mean residence time of oxaliplatin after IP administration revealed that slow and continuous erosion of the MVL particles yielded a sustained drug release. Thus, oxaliplatin-loaded MVL depots presented in this study have potential for use in the treatment of colorectal cancer.

Local Delivery System Using Thermosensitive Hydrogel and Drug Loading Microspheres for Cartilage Repairing

2014 ◽  
Vol 898 ◽  
pp. 300-303 ◽  
Author(s):  
Lei Wang ◽  
Gang Wu
Keyword(s):  
Drug Release ◽  
Delivery System ◽  
Ring Opening ◽  
Drug Loading ◽  
Local Drug Delivery ◽  
Burst Release ◽  
Transition Diagram ◽  
Thermosensitive Hydrogel ◽  
Local Drug Delivery System

A local drug delivery system constituted by hybrid microsphere/thermosensitive hydrogel was fabricated for Osteoarthritis (OA) therapy in the research. The hydrogel were synthesized by ring-opening copolymerization. Microsphere was fabricated by O/W emulsion and solution evaporation method. The properties of the products were characterized by 1HNMR, FTIR and phase transition diagram. The microsphere/hydrogel was prepared for in vitro drug release research. The results showed microsphere/hydrogel hybrid system can alleviate initial burst release. After 650 hours, only 60 percent of the drugs were released. Kinetics research implied the drug release is controlled by diffusion/erosion mechanism.

scholarly journals Synthesis, Degradation, Biocompatibility and Drug Release Studies of Bis 2-Hydroxy Ethyl Terephthalate-based Poly(Mannitol-Citric-Sebacate) Ester

2016 ◽  
Vol 1 (1) ◽  
pp. 9-16
Author(s):  
Athira K Sunil ◽  
Sarkar K ◽  
Kaushik Chatterjee
Keyword(s):  
Drug Release ◽  
Drug Carrier ◽  
Condensation Process ◽  
Burst Release ◽  
Release Studies ◽  
Biodegradable Poly ◽  
Model Drug ◽  
Melt Condensation

Bis 2-Hydroxy Ethyl Terephthalate-based biodegradable poly(mannitol-citric-sebacate) has been synthesized by catalyst-free melt condensation process using two different diacids and Bis 2-Hydroxy Ethyl Terephthalate with D-mannitol as monomers having a potential to be metabolized in vivo. The biocompatibility of the polymer, Bis 2-Hydroxy Ethyl Terephthalate-poly(mannitol-citric-sebacate) has been tested using human primary stromal cells. In vitro degradation of Bis 2-Hydroxy Ethyl Terephthalate-poly(mannitol-citric-sebacate) polymer in Phosphate Buffered Saline solution carried out at physiological conditions indicates that the degradation goes to completion after 23 days. The usage of Bis 2-Hydroxy Ethyl Terephthalate-poly(mannitol-citric-sebacate) polymer as a drug carrier has been analyzed by doping the polymer with Doxorubicin model drug and the release rate has been studied by mass loss over time. The cumulative drug-release profiles exhibit a biphasic release with an initial burst release and cumulative 100 percent release within 14 days.

scholarly journals Development of Dry Powder Inhaler Containing Prothionamide-PLGA Nanoparticles Optimized Through Statistical Design: In-vivo Study

2017 ◽  
Vol 4 (1) ◽  
pp. 30-40 ◽  
Author(s):  
Sujit K. Debnath ◽  
Saisivam Srinivasan ◽  
Monalisha Debnath
Keyword(s):  
Particle Size ◽  
Drug Release ◽  
Dry Powder Inhaler ◽  
Burst Release ◽  
Dry Powder ◽  
Box Behnken Design ◽  
Pulmonary Administration ◽  
Aerodynamic Particle Size

Objective:The objective of the present work was to formulate Prothionamide (PTH) nanoparticles using Poly lactic co-glycolic acid (PLGA), optimized by Box-Behnken Design and further modification to dry powder inhaler followed byin-vivostudy.Methods:Poly-lactic co-gycolic acid (PLGA), a biodegradable polymer was used to coat Prothionamide by solvent evaporation technique. Formulation was optimized using Box-Behnken Design. Response surface curve and desirability factors helped in the selection of optimum formulation of PTH nanoparticles. Dry powder inhaler was prepared by adding inhalable grade lactose to optimize PTH nanoparticles. Mass median aerodynamic diameter (MMAD) was carried out using Andersen Cascade Impactor (ACI) to demonstrate its suitability in the pulmonary administration.In-vitrodrug release of dry powder inhaler was carried out in simulated lungs fluid. Correlationin-vitrotoin-vivowas established after performing animal experiment.Results:FTIR study reveals no chemical interaction between PTH, lactose and PLGA as the principle peaks was retained with same intensity in the physical mixture. Scanning electron microscope showed the spherical shape and aerodynamic particle size was found to be 1.69µm. Drug release study showed initial burst release followed by zero order release.In-vivomodel confirmed the presence of PTH after 24h. Aerodynamic particle size and the release profile revealed the suitability of PTH loaded nanoparticles containing dry powder inhaler for the pulmonary administration.Conclusion:Prepared DPI containing PTH nanoparticles can improve in the management of tuberculosis by increasing PTH residency in the lungs tissue for prolong period of time.

scholarly journals RADITYA ISWANDANA, KURNIA SARI SETIO PUTRI, RANDIKA DWIPUTRA, TRYAS YANUARI, SANTI PURNA SARI, JOSHITA DJAJADISASTRA

2017 ◽  
Vol 9 (5) ◽  
pp. 109
Author(s):  
Raditya Iswandana ◽  
Kurnia Sari Setio Putri ◽  
Randika Dwiputra ◽  
Tryas Yanuari ◽  
Santi Purna Sari ◽  
...  
Keyword(s):  
Drug Release ◽  
Sodium Tripolyphosphate ◽  
In Vitro Release ◽  
Entrapment Efficiency ◽  
Release Profile ◽  
Process Efficiency ◽  
Drug Release Profile ◽  
Eudragit L100

Objective: Drug delivery to the colon via oral route can be directly treated a variety of diseases in the colon, such as fibrosis. Tetrandrine is a drug that has anti-fibrosis effects. In this study, chitosan-tripolyphosphate (TPP) beads containing tetrandrine was made and evaluated for in vitro release profile and in vivo targeted test.Methods: Chitosan-TPP tetrandrine beads were prepared by ionic gelation method with variation in sodium tripolyphosphate concentration: 3% (Formula 1), 4% (Formula 2), and 5% (Formula 3). All formulae were characterized for its morphology, particle size, moisture content, process efficiency, entrapment efficiency, thermal character, crystallinity, and swelling. Then, the best formula was coated with HPMCP HP-55, CAP, Eudragit L100-55, or Eudragit L100 prior to drug release profile in vitro and in vivo test.Results: Beads from all formulae had an average size: 920.50±0.04 µm, 942.21±0.08 µm, and 1085.95±0.03 µm; Water content: 7.28±0.003%, 5.64±0.005%, and 6.84±0.004%; Process efficiency: 29.70%, 28.96%, and 29.70%; Entrapment efficiency: 16.20±0.63%, 17.02±0.37%, and 20.42±0.70% for Formula 1, 2, and 3, respectively. In addition, the results of in vitro cumulative drug release were 67.36%, 76.04%, 83.12%, 83.21%, 40.16%, 37.98%, 45.86%, 41.71% for Formula 3A-3H, respectively.Conclusion: It can be concluded that Formula 3D (CAP 15%) was chosen as a formulation with the best in vitro profile. Moreover, the in vivo targeted test showed that Formula 3D was able to deliver the beads to the intestine compared to the control beads.

Periodontal Treatment by Local Drug Delivery Using Resorbable Base Material

1988 ◽  
Vol 2 (2) ◽  
pp. 401-404 ◽  
Author(s):  
T. Noguchi ◽  
M. Fukuda ◽  
I. Ishikawa
Keyword(s):  
Drug Delivery ◽  
Gingival Crevicular Fluid ◽  
Clinical Manifestations ◽  
Base Material ◽  
Local Drug Delivery ◽  
Subgingival Plaque ◽  
Initial Examination ◽  
Microbial Composition

The effects of local drug delivery to the subgingival plaque flora using resorbable base material were evaluated by the study of microbial composition in periodontal pockets and clinical manifestations of disease. In vitro, the drug used in this study was released within 24 hr from the hydroxypropylcellulose (HPC) strips. In vivo release of the drug from strips was also measured in nine patients who had, contralaterally, deep pockets of more than 5 mm. A tetracycline (TC)-containing HPC strip was inserted in one pocket, and a blank strip without TC was inserted in the other pocket. The amount of TC in the gingival crevicular fluid (GCF) 24 hr after insertion of the strip was significantly higher than that of the control. Ten subjects, who had at least three pockets greater than 4 mm in depth, were selected from 50 volunteers after an initial examination. HPC strips containing TC, chlorhexidine (CH), and control (base material) were inserted into each pocket three times a week. Clinical and microbiological changes ascertained by darkfield microscopy were monitored over three weeks. Reduction of both probing depth and bleeding-on-probing was observed only in the pockets in which TC was administered. Changes of microbial composition of subgingival plaque were, however, found in both TC- and CH-treated pockets. The percentages of spirochetes and motile rods were remarkably reduced in these pockets.

Sign in / Sign up

Export Citation Format

Share Document